Exploring the antidepressant-like effect of stigmasterol using network pharmacology with molecular docking and in vivo experimental validation Authors: Robert Peter Biney, Isaac Blessed Mensah, Akua Afriyie Karikari, Aaron Opoku Antwi, Abigail Wortsi, Albert Dwamena Nkansah, Gyan Nana Kyere Barnieh, Isaac Tabiri Henneh Published: 2025 ABSTRACT With a global prevalence of 3.8% and affecting approximately 300 million people, depression remains a global burden calling for renewed efforts including novel antidepressants to address treatment gaps. Stigmasterol, an unsaturated naturally abundant phytosterol with reported neuropsychiatric activity in preclinical studies, was studied for potential antidepressant-like activity and mechanism of action using computational and experimental approaches. Using network pharmacology, we identified potential key targets of major depressive disorder and stigmasterol (STG) by analysing intersection genes for protein-protein interaction, Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. We subsequently carried out molecular docking of stigmasterol with key targets identified to confirm antidepressant activity and potential mechanism(s) while the forced swim test (FST) and tail suspension test (TST) were used for experimental validation. To experimentally validate the involvement of monoaminergic mechanism(s) in STG’s action, mice were pretreated with selective inhibitors of monoamine synthesis and storage after which the antidepressant-like effects of STG was re-evaluated in FST. Forty intersection target genes were obtained with AKT1, TP53 and IL1B as well as MAOB, MAOA and SLC6A4 being identified as key targets. GO and KEGG enrichment analysis further reinforced the involvement of monoamine regulation, especially serotonin. Molecular docking showed STG interacts with SLC6A4 (-9.732 kcal mol-1), MAOA (-12.471 kcal mol-1) and MAOB (-14.614 kcal mol-1) further buttressing monoaminergic involvement. STG demonstrated significant antidepressant-like effects similar to fluoxetine-treated mice in both FST and TST. This antidepressant action was significantly influenced by serotonin neurotransmission. Overall, we confirmed the antidepressant-like activity of STG and its possible multitarget potential in depression management. Introduction Mental health disorders are among the leading causes of the global health-related burden. Anxiety and depression disorders are the two most incapacitating mental diseases according to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD)1. Depression affects over 300 million people globally and is the leading cause of disability worldwide2 with significant aspects of the cellular and molecular etiology of depression largely unknown3. Approximately 17% of men and 25% of women experience major depressive episodes during the course of their lifetimes, and recurrence is common, with up to 60% of persons experiencing more than one major depressive episode in their lifetime4. Despite the availability of several treatment options5 and the strong evidence of actions to lessen the impact, no significant decline in global prevalence has been recorded since 19901. Even though modern antidepressants have saved lives and helped a number of people, they are still ineffective in about one-third of patients, failing to elicit at least a partial response, and only about 30% of patients experience complete remission6,7. These current antidepressants take weeks to months to achieve full effect, sometimes even increasing the risk of suicidal thoughts and actions, and morbidity during this lag period8. In addition, over 50% of people receiving antidepressants report negative side effects such weight gain, drowsiness, sexual difficulties, emotional numbness, and withdrawal symptoms despite their effectiveness9. The complexities of depression and inadequacies of current antidepressants require innovative approaches in the search for novel antidepressants. That requires evaluating novel antidepressants in a battery of models that assess potential effect in various hypotheses of depression10. The “one drug–one target–one disease” model in drug discovery which simplifies the screening of compounds and reduces unwanted side effects, has shown limited efficacy, particularly in complex heterogeneous diseases like major depressive disorder11. Thus network pharmacology, which is the field of pharmacology that integrates and coordinates intricate networks involving drug targets and diseases to facilitate a comprehensive understanding of complex pharmacological interactions12 remains a good approach in identifying multiple targets/pathways which may be working in concert to contribute to the pathophysiology of depression and can thus facilitate the discovery of novel antidepressants that can modulate multiple targets simultaneously and enhance therapeutic efficacy. The coupling of network pharmacology with molecular docking provides additional benefit of understanding the potential mechanisms underlying action of small molecules on targets and pathways implicated in a particular disorder13. This research thus uses this approach in tandem with experimental validation using in-vivo studies to evaluate the antidepressant-like activity of stigmasterol, an unsaturated phytosterol. This compound has reported anti-inflammatory14, neuroprotective15 and acute antidepressant-like16 properties in rodent models. The workflow and schematic presentation of the approach used in the study is summarized in Figure 1Fig. 1Schematic presentation of experimental procedures. Schematic presentation of experimental procedures. Results Potential stigmasterol targets and depression targets To examine the relationship between stigmasterol and major depressive disorders, a preliminary screening was conducted to retrieve possible targets of stigmasterol. From the PharmMapper database, 203 targets were retrieved, 137 from GeneCard database and 100 from SwissTargetPrediction. A total of 394 targets were subsequently obtained after unification and removal of duplicates (Figure 2a).Fig. 2Network construction; Targets of stigmasterol obtained from the PharmMapper, GeneCards and SwissTargetPrediction databases (a) Major depression disorder Venn diagram targets obtained using the following databases: GenCard, OMIM, DisGenet and PharmGKB (b), identified by network pharmacology using the databases: GenCard, OMIM, DisGenet and PharmKGB. (c) A Venn diagram identifying the forty targets that stigmasterol and major depression disorder have in common (d) A protein-protein interaction (PPI) network of the forty intersecting targets, constructed using STRING (PPI) network of 40 intersecting targets. (e) Histogram and network of the 25 core targets, based on degree of centrality, constructed in Cytoscape using the CytoHubba plugin. The greater the intensity of the colour of the circular nodes, the higher their degree values. Network construction; Targets of stigmasterol obtained from the PharmMapper, GeneCards and SwissTargetPrediction databases (a) Major depression disorder Venn diagram targets obtained using the following databases: GenCard, OMIM, DisGenet and PharmGKB (b), identified by network pharmacology using the databases: GenCard, OMIM, DisGenet and PharmKGB. (c) A Venn diagram identifying the forty targets that stigmasterol and major depression disorder have in common (d) A protein-protein interaction (PPI) network of the forty intersecting targets, constructed using STRING (PPI) network of 40 intersecting targets. (e) Histogram and network of the 25 core targets, based on degree of centrality, constructed in Cytoscape using the CytoHubba plugin. The greater the intensity of the colour of the circular nodes, the higher their degree values. To obtain the targets for major depressive disorder; GeneCard, OMIM, DisGenet and PharmGKB databases were searched with keywords “major depressive disorders”. 201 targets were retrieved From the GeneCard (Relevance score>30.05), 29 from OMIM, 229 from Disgenet (Score_gda>0.4) and 79 from PhamGKB (p<0.05). After duplicates were removed, 445 targets were obtained for major depressive disorder. 7 common target proteins were obtained; serotonin transporter (SLC6A4), serotonin receptor 2 A (5-HT2AR), FK506 binding protein 5 (FKBP5), Methylenetetrahydrofolate reductase (MTHFR), Tryptophan hydroxylase 2 (TPH2), Catechol-O-methyltransferase (COMT) and Dopamine D3 receptor (DRD3) (Figure 2b). The intersection of stigmasterol and major depressive disorder targets resulted in 40 common targets (Figure 2c) Protein-protein interaction network and core target screening Interactions with medium confidence was chosen after the 40 intersection targets were imported into the STRING database. As seen in Figure 2d, the resultant PPI network had 40 nodes and 240 edges, each of which represented a unique protein-protein interaction (PPI). The average node degree, which shows how many targets are connected to the network, was found to be 12. The average local clustering coefficient, which shows how many targets are connected to the network, was 0.701. The network was imported to Cytoscape 3.10.0 and the cytohubba plugin was used to compute the degree with the top 25 hub genes presented in figure 2e. Function enrichment analysis The 40 intersection targets associated with both stigmasterol and major depressive disorders were further used for gene ontology (GO) enrichment and KEGG pathway analysis using ShinyGO. Targets were analyzed under three levels, namely biological processes (BP), molecular function (MF) and cellular components (CC). Most BPs enriched were associated with propagation of stimuli and cell signaling (Fig. 3A). For targets analyzed under molecular function (MF), monoamine transmembrane transporter activity and also kinase activity were significantly highlighted (Fig. 3B). According to the CC of GO analysis, stigmasterol targets were primarily located around neuronal cells (Fig. 3C). Although further KEGG analysis revealed the involvement of the intersection genes in multiple cancer pathways, the analyses also show significant involvement of genes involved in disorders with dysfunction of the serotonergic synapse as the pathway most relevant in depression (Fig. 3D). Fig 3E indicates stigmasterol influences five key targets (SERT, MAOA, Cyt P450, MEK1 and Raf) in the enrichment analysis of the serotonergic synapse pathway.Fig. 3GO and KEGG pathway analysis using ShinyGO tool. A-C shows results from GO analysis. D-E shows results obtained from the KEGG pathway analysis. False discovery rate (FDR) presents the degree of enrichment. The size of the dot indicates number of target genes involved in the pathway with increasing size indicating greater number. Various colors of dots and line indicate diverse fold enrichment values. GO and KEGG pathway analysis using ShinyGO tool. A-C shows results from GO analysis. D-E shows results obtained from the KEGG pathway analysis. False discovery rate (FDR) presents the degree of enrichment. The size of the dot indicates number of target genes involved in the pathway with increasing size indicating greater number. Various colors of dots and line indicate diverse fold enrichment values. Molecular docking studies Five common target genes of major depressive disorder and stigmasterol (AKT1, IL-1β, MAOA, MAOB and SLC6A4) (Table 1) were selected for the molecular docking study based on the compound-target network construction, protein‒protein interactions (PPIs) and KEGG analyses. These targets play crucial roles in the pathophysiology of depression, especially relating to the monoamine neurotransmitters synthesis and catabolism. Stigmasterol exhibited a favorable docking score against MAOB, AKT1, MAOA, and SLC6A4 respectively and had better docking scores than reference ligands for AKT1, MAOA and MAOB (Table 2). This suggests good binding affinities, likely due to hydrogen bonds formed with specific amino acids at the active binding pockets; hydrogen bond with MET436 for MAOB, SER438 and ASN177 for SLC6A4, and SER205 for AKT1 (Figure 4). In addition, hydrophobic and electrostatic interactions were observed between stigmasterol and specific residues in the binding pocket (Figure 4). Further analysis for Induced-fit binding showed stigmasterol to have comparable IFD scores to the reference ligand and the co-crystalized ligand, indicating good binding in binding pocket. However, stigmasterol showed low affinity for IL-1β with a docking score of −5.857kcal mol−1 and a highly positive IFD scores though comparable to the reference ligand and the co-crystalized ligand. To further assess the binding affinities, Prime MM-GBSA analysis was carried to obtain the binding free energy. Stigmasterol showed good affinities ranging from −56.54 to −79.80 kcal mol−1 (Table 2).Table 1Selected target protein, reference ligands and receptor grids used in molecular docking.TargetPDBReference ligandReceptor Grid (X \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} Y \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} Z)AKT3O96AKT Inhibitor X8.59 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} −7.07\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} 13.13IL1B8C3UCP-31398−18.34\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document}−4.64\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document}- 42.41MAOA2Z5XIsocarboxazid40.61 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} 26.84 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document}−14.80SLC6A45I73Fluoxetine32.91 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} 184.4 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$0 \times$$\end{document} 1.62MAO-B2BK3Selegiline15.85 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} 127.68 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} 23.76Fig. 4Molecular docking results; Binding interactions and pose of stigmasterol docked to: monoamine oxidase A (a), monoamine oxidase B (b), serotonin transporter (c), serine/threonine kinase AKT 1(d) and interleukin-1β (e). Table 1Selected target protein, reference ligands and receptor grids used in molecular docking.TargetPDBReference ligandReceptor Grid (X \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} Y \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} Z)AKT3O96AKT Inhibitor X8.59 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} −7.07\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} 13.13IL1B8C3UCP-31398−18.34\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document}−4.64\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document}- 42.41MAOA2Z5XIsocarboxazid40.61 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} 26.84 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document}−14.80SLC6A45I73Fluoxetine32.91 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} 184.4 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$0 \times$$\end{document} 1.62MAO-B2BK3Selegiline15.85 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} 127.68 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} 23.76 Selected target protein, reference ligands and receptor grids used in molecular docking. Molecular docking results; Binding interactions and pose of stigmasterol docked to: monoamine oxidase A (a), monoamine oxidase B (b), serotonin transporter (c), serine/threonine kinase AKT 1(d) and interleukin-1β (e). Table 2Docking analysis of stigmasterol -Targets interactions.Docking scores (kcal mol−1)TargetStigmasterolReference ligandCo-crystallized ligandAKT (3O96)−12.545−9.339−10.119IL1 β (8C3U)−5.857−10.860−10.608MAOA (2Z5X)−12.471−8.664−9.650MAOB (2BK3)−14.614−9.048−7.144SLC6A4 (5I73)−9.732−10.964−9.510Induced fit docking scores (kcal mol−1)TargetStigmasterolReference ligandCo-crystallized ligandAKT (3O96)−692.97−693.06−692.99IL1 β (8C3U)83729.2983718.3683723.93MAOA (2Z5X)−520.27−509.94−510.13MAOB (2BK3)−2020.17−2010.71−2014.32SLC6A4 (5I73)−1496.45−1490.28−1484.36Prime MM-GBSA, ΔG (kcal mol−1)TargetStigmasterolReference ligandCo-crystallized ligandAKT (3O96)−79.80−74.21−101.23IL1 β (8C3U)−65.04−73.00−43.52MAOA (2Z5X)−75.91−33.8−68.74MAOB (2BK3)−74.89−52.8−59.48SLC6A4 (5I73)−56.54−69.18−45.57 Table 2Docking analysis of stigmasterol -Targets interactions.Docking scores (kcal mol−1)TargetStigmasterolReference ligandCo-crystallized ligandAKT (3O96)−12.545−9.339−10.119IL1 β (8C3U)−5.857−10.860−10.608MAOA (2Z5X)−12.471−8.664−9.650MAOB (2BK3)−14.614−9.048−7.144SLC6A4 (5I73)−9.732−10.964−9.510Induced fit docking scores (kcal mol−1)TargetStigmasterolReference ligandCo-crystallized ligandAKT (3O96)−692.97−693.06−692.99IL1 β (8C3U)83729.2983718.3683723.93MAOA (2Z5X)−520.27−509.94−510.13MAOB (2BK3)−2020.17−2010.71−2014.32SLC6A4 (5I73)−1496.45−1490.28−1484.36Prime MM-GBSA, ΔG (kcal mol−1)TargetStigmasterolReference ligandCo-crystallized ligandAKT (3O96)−79.80−74.21−101.23IL1 β (8C3U)−65.04−73.00−43.52MAOA (2Z5X)−75.91−33.8−68.74MAOB (2BK3)−74.89−52.8−59.48SLC6A4 (5I73)−56.54−69.18−45.57 Docking analysis of stigmasterol -Targets interactions. In Vivo experimental validation Antidepressant-like activity Forced swim test As shown in figure 5b, a dose-dependent antidepressant-like effect is exhibited by fluoxetine-treated mice with doses at 10 and 30 mg kg−1 showing the most significant reduction in duration of immobility (p<0.001). Though not significant, a marginal reduction of immobility duration was observed in mice treated with stigmasterol 1, 3 and 10 mg kg−1 in a dose-dependent manner. At doses of 30 and 100 mg kg−1 stigmasterol exhibited significant antidepressant-like effects (p<0.05 and p<0.01 respectively) (Figure 5a). Dose response curve indicated marginal difference in the efficacy of stigmasterol and fluoxetine (STG: EC50=3.385; Emax = 58.47 and FLX: EC50 = 2.711; Emax = 78.55 mg kg−1 respectively) in reducing immobility time with fluoxetine being more potent (Figure 5c).Fig 5.Effect of stigmasterol and fluoxetine on the duration of immobility in mice in the forced swim test (a) and tail suspension test (b). Dose response curves comparing efficacy and potency in FST (c) and TST (f). Data are presented as mean ± SEM (n=7), * = p < 0.05, ** = p<0.01, *** = p<0.001. Effect of stigmasterol and fluoxetine on the duration of immobility in mice in the forced swim test (a) and tail suspension test (b). Dose response curves comparing efficacy and potency in FST (c) and TST (f). Data are presented as mean ± SEM (n=7), * = p < 0.05, ** = p<0.01, *** = p<0.001. Tail suspension test A dose-dependent antidepressant-like effect was exhibited by stigmasterol (Figure 5d). Mice treated with 100 mg kg−1 significantly reduced duration of immobility similar to fluoxetine 1 - 10 mg kg−1 (p<0.01). Mice treated with 30 mg kg−1 of fluoxetine showed the most significant reduction in duration of immobility (p<0.001) (Figure 5e). Dose response analyses revealed differences in the efficacy and potency between stigmasterol and fluoxetine in reducing immobility time in TST (figure 5f). Stigmasterol had EC50 = 8.847 and Emax = 72.33 while fluoxetine had EC50 = 2.334 and Emax = 96.53 mg kg−1. Mechanisms underlying antidepressant-like activity Influence of monoamines As indicated in Figure 6a the observed antidepressant-like effect of fluoxetine 30 mg kg−1 and imipramine 30 mg kg−1 in forced swim test was reversed significantly when mice were pre-treated with a single dose of vesicular monoamine transporter inhibitor, reserpine (1 mg kg−1). A marginal reversal of antidepressant-like effect is observed in the stigmasterol 30 mg kg−1 group (Figure 6a).Fig. 6Influence of reserpine (a), AMPT (b) pCPA (c) pizotifen (d), ondansetron (e) and propranolol (d) on immobility time in STG (30 mg kg−1), FLX (30 mg kg−1) and IMI (30 mg kg−1) treatments. Results indicate mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001. Two-way ANOVA followed by Sidak multiple comparison test. Influence of reserpine (a), AMPT (b) pCPA (c) pizotifen (d), ondansetron (e) and propranolol (d) on immobility time in STG (30 mg kg−1), FLX (30 mg kg−1) and IMI (30 mg kg−1) treatments. Results indicate mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001. Two-way ANOVA followed by Sidak multiple comparison test. In the presence of AMPT (100 mg kg−1), the observed antidepressant-like effects of stigmasterol and fluoxetine are preserved while that of imipramine were reversed (Figure 6b). However, pre-treatment with the tryptophan hydroxylase inhibitor pCPA (100 mg kg−1 i.p. for 4 days) significantly reversed (p<0.01) the observed antidepressant-like effects of stigmasterol and fluoxetine but not imipramine (Figure 6c). Whereas marginal reversal of antidepressant-like effect is observed in the fluoxetine-treated mice when pretreated with pizotifen, a 5-HT2 receptor antagonist, no such reversal was observed in the stigmasterol-treated mice (Figure 6d). Figure 6e shows that antagonizing 5-HT3 receptors using 5-HT3 selective receptor antagonist, ondansetron, reverses the antidepressant-like effects of stigmasterol significantly but only marginally in fluoxetine-treated animals. Furthermore, the antidepressant-like behaviors of stigmasterol were preserved in mice pretreated with beta 2 adrenoceptor blocker, propranolol (Figure 6f). Discussion The World Health Organization (WHO) projects that by 2030, depression will be the leading cause of disease worldwide17. In terms of treatment, less than half of MDD patients achieve remission with currently prescribed antidepressants while one-third of MDD patients fail to respond to treatment7. The dominant view for decades has been that depression is caused by abnormalities in monoamine neurotransmitters: serotonin, norepinephrine and dopamine, which serves as a significant rationale for the use of antidepressants18. Despite these challenges with current treatment regimen, the development of new drugs to treat MDD has been surprisingly slow for the past few decades19. One strategy to curb this current dearth of novel antidepressants is the pharmacological characterization of scaffold molecules that feed the pipeline of lead compounds for development as novel antidepressants with superior therapeutic property. This study thus sought to investigate the antidepressant-like potential of the plant sterol, stigmasterol, as a scaffold, and the possible mechanism(s) that may contribute to its effects. As an unsaturated phytosterol, stigmasterol is a member of the tetracyclic triterpene class. It can be found in vegetable oils15. Pharmacologic properties such as antinociceptive, anti-inflammatory, antiarthritic, neuroprotective, antitumor and others have already been demonstrated20. Stigmasterol is also known to modulate reactive oxygen species (ROS) levels, which adds to its neuroprotective effects15. Previous studies by Ghosh et al.16 reported an acute antidepressant-like activity of stigmasterol in the tail suspension test at a single dose of 20 mg kg−1. Further findings suggested the antidepressant-like activity observed was via modulation of the glutamatergic system16. While this study points to the potential antidepressant activity of stigmasterol, further gaps in knowledge needed to be filled with regards to the pharmacological properties of stigmasterol. We used network pharmacology to gain further understanding on the potential mechanism(s) behind the antidepressant actions of stigmasterol21. Screening for common targets of stigmasterol and major depressive disorders yielded forty gene targets that undergo intricate interactions to modulate depression through multiple pathways. Top three targets based on their degree were AKT serine/threonine kinase 1 (AKT1), Tumor Protein P53 (TP53) and interleukin-1β (IL-1b). Notably, MAOA, MOAB and SLC6A4 which are also strongly implicated in serotonergic and dopaminergic signaling and significant contributors to the monoamine hypothesis of depression were identified as pivotal genes modifiable by stigmasterol based on the degree analysis22,23. The pathogenesis of depression is complex and involves multiple signal transduction pathways and molecular changes24. AKT is a serine/threonine protein kinase that plays a central role in the signaling network involving MAPK and mTOR, and which regulates multiple cellular processes including glucose metabolism, apoptosis, cell proliferation, transcription and cell migration21. The AKT pathway is an essential signaling pathway in neurons, which is widely expressed in emotion-related regions of the brain, playing a key role in the survival, proliferation, and apoptosis of neurons25. The involvement of AKT in neuropsychiatric disorders has been recently established showing that the depletion of AKT evokes depressant-like behavior21,25. AKT mainly consists of AKT1, AKT2, and AKT3 subtypes. AKT1 is the most widely expressed26 and its activation increases neuronal survival against hypoxic stress and nitric oxide toxicity especially in the hippocampal regions, a region highly implicated in major depressive disorder27. Importantly, AKT1 pathway is involved in the mechanisms underlying rapid-acting antidepressants, such as ketamine, by promoting synaptic plasticity and neuroplasticity through the PI3K-Akt-mTOR signaling pathway. Activation of this pathway stimulates protein synthesis, leading to the formation of new synapses and the reversal of synaptic deficits associated with depression28. This finding that stigmasterol may modulate AKT1, a target increasingly recognized as central to rapid antidepressant action, offers new mechanistic insights earmarked for development of more effective antidepressants29. Thus, the finding that stigmasterol modifies the gene provides novel mechanistic insights that are required for novel antidepressants to be superior therapeutics. Additionally, accumulating evidence suggests the involvement of neuroinflammatory processes in the pathophysiology of major depressive disorder and resistance to antidepressant treatment30,31. Indeed, stigmasterol has been shown to possess anti-inflammatory effects14. This finding coupled with the fact that we found significant potential gene modulation of interleukin-1β, a key pro-inflammatory cytokine, suggest that stigmasterol will possess additional mechanisms that would enhance the therapeutic efficacy in managing the gaps in current depression treatment. IL-1b serves as one of the main mediators in the cross-talk between the central nervous system and the immune32,33 and its link with MDD is underscored by meta-analyses confirming higher concentrations of IL1B in individuals with depression33. Moreover, IL-1β levels have been associated not only with the presence of depressive symptoms but also with their severity and the degree of resistance to conventional antidepressant treatments especially in elderly patients34. Therefore, antidepressants with multimodal action including modulation of IL-1b would be significant in the search of novel antidepressants that address current treatment gaps. Evidence of stigmasterol’s possible multimodal potential was further substantiated by possible modulation of monoamines, as predicted involvement of monoamine oxidase A (MOAA), monoamine oxidase A (MOAB) and Solute Carrier Family 6 Member 4 (SLC6A4) in its mechanism of action. Monoamine oxidase enzymes (MOAA and MOAB) are enzymes that catalyze the oxidative deamination of monoamine neurotransmitters in the brain35. The oxidative deamination of serotonin, norepinephrine and dopamine causes the reduction in level of these monoamines, implicated in several affective disorders such as major depressive disorders36. Monoamine oxidase inhibitors such as isocarboxazid have long been used in the management of depression, proving it a potent target for discovery and development of antidepressants22,37. Further highlighting the multimodal potential of stigmasterol, we observed its potential modulatory effect on SLC6A4 (Solute Carrier Family 6 Member 4), which encodes the serotonin transporter protein which regulates serotonin levels by re-uptaking serotonin from the synaptic cleft12,38. The serotonin transporter has received a lot of attention in MDD research, in part since it is the primary mechanism to decrease extracellular 5-HT, but also because it is the target of the most commonly used antidepressant drugs39. The serotonin transporter is one of the most investigated parameters of the serotonergic system in depression research. The interest in this transporter stems down from antidepressants such as selective serotonin reuptake inhibitors (SSRIs) directly binding to serotonin transporter inhibiting serotonin reuptake serving as the most efficacious pharmacological treatment target for depressive disorders39,40. Thus, while we find stigmasterol to be interacting with unconventional targets described above, it also interacts with known antidepressant targets like the serotonin transporter. This points to the multimodal utility of this small molecule as a great scaffold. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was employed to further analyze the 40 intersecting genes, revealing numerous pathways as well as highlighting associations with other diseases. The GO enrichment analysis revealed that cellular response to stimuli, signal transduction, nitric oxide synthase regulation, monoamine transmembrane transporter activity and tyrosine kinase activity pathway are associated with antidepressant activity of stigmasterol. The results of the KEGG pathway enrichment analyses showed more enriched pathways involved in the pathogenesis of various cancers. This is in line with literature as the anticancer potential of stigmasterol are continually being investigated15,41–43. Nevertheless, PI3K/AKT signaling pathway and the MAPK signaling pathway were among the top 5 enriched pathways based on the false discovery rate (FDR). Accumulating evidence suggest the involvement PI3K/AKT signaling pathway and MAPK signaling pathway in the pathogenesis of major depressive disorders21. PI3K/AKT pathway plays a key role in stress-induced neuroinflammation resulting in depression by the reduction of its activity. This pathway is also involved in the regulation of neurogenesis. This presents it as an effective potential target for development of novel antidepressants25. MAPK signaling pathway has also been identified to be associated in the development of depression, with increasing evidence supporting it involvement in the pathogenesis, symptomatology, and treatment of depression21,44. Furthermore, the KEGG pathway analysis highlighted the critical role played by the serotonergic synapse within the designated network. This corroborates the network pharmacology assessment that shows significant modulation of serotonergic transporters. In summary, our findings from the network pharmacology indicated that stigmasterol may exhibit antidepressant activity through increasing neuronal survival, attenuating neuroinflammation and modulation of monoamines, especially serotonin and confirms indicates a promising, multifaceted approach leveraging stigmasterol as potential multitarget therapeutic agent. Building on the network pharmacology findings, molecular docking was performed to evaluate the binding affinity and orientation of stigmasterol toward key targets implicated in rapid onset antidepressant activity, treatment resistant depression or the classical monoamine hypothesis of depression29,34,45. The analysis included docking against AKT1, IL-1β, MAOA, MAOB and SLC6A4. The best pose of each ligand was then analyzed using induced fit docking (IFD) based on the extra precision docking scores, after which prime MM-GBSA binding energies were calculated. In Glide docking, the receptor is held rigid when the ligand is docked into its binding site which may provide false estimations of binding affinities as it is postulated that proteins undergo movement upon interaction with small molecules46. However, induced-fit binding is a docking protocol which permits these shifts or movements when proteins bind to a ligand providing a more accurate prediction of binding affinities47. MM-GBSA provides an even more reliable rating of binding affinities by utilizing molecular mechanics and free energy calculations to consider enthalpic contributions in ligand interaction with protein46,48. Notably, stigmasterol displayed strong binding affinity for MAOA (−75.91 kcal mol−1) and MAOB (−74.89 kcal mol−1) surpassing that of the reference ligands, isocarboxazid (−33.8 kcal mol−1) and selegiline (−52.8 kcal mol−1) respectively as well as the co-crystalized ligands. This finding is corroborated by similar observations in the extra precision (XP) docking scores and IFD. This observation confirms results obtained in the KEGG pathway enrichment analyses indicating MAOA a as a key target of stigmasterol at the serotonergic synapse. Isocarboxazid and selegiline are both standard drugs used in the management of mood disorders particularly severe and treatment resistant depression49,50, this further reinforces the potential of stigmasterol as a scaffold for discovery of novel antidepressants to bridge current gaps in treatment of depression. Additionally, stigmasterol presented a strong affinity for AKT1 (−79.80 kcal mol−1), higher than the reference ligand (AKT inhibitor X) though not higher than the co-crystalized ligand (−101.23 kcal mol−1). This strong affinity with this key player in rapid onset antidepressant action may confer a desirable fast onset of antidepressant effect on stigmasterol29. Though stigmasterol (−56.54 kcal mol−1) did not have better docking scores compared to the reference ligand fluoxetine (−69.18 kcal mol−1) for SLC6A4, it exhibited a good affinity as negative scores denotes favorable interactions, with lower values reflecting higher binding affinity in molecular docking51. Stigmasterol however produced mild docking score against IL-1β (−5.857 kcal mol−1). Though it provided a conflicting good affinity of −65.04 kcal mol−1 in the MM-GBSA calculation, the IFD was 83729.29 kcal mol−1 indicating presence of unfavorable interactions. It is worth noting that there are no standard drugs that bind directly to IL-1β. Drugs such as anakinra, inhibit the activity of IL-1β by binding to soluble IL-1 receptor 1, thereby inhibiting the interaction of IL-1β with its cell surface target to elicit an effect. Therefore, most research focus on developing pharmacological agents that inhibit IL-1β-IL-1 receptor 1 (IL-1R1) interaction52. Stigmasterol may be modulating the action of IL-1β as indicated in the network pharmacology via other pathways and not by directly binding to the cytokine. Results obtained from prior in-silico study pointed to the involvement of monoamine modulation in the antidepressant activity of stigmasterol. To confirm this in in vivo study, synthesis or storage of specific neurotransmitters were inhibited prior to drug treatment to diminish antidepressant action of drug acting via their modulation. But first, two murine behavioral despair models of depression were used to experimentally validate the antidepressant-like activity of depression as well as evaluate the dose-response of stigmasterol. The forced swim test and tail suspension test have long been used to evaluate the antidepressant-like activity of novel compounds and crude extracts due to their good predictive validity53. Stigmasterol exhibited an antidepressant-like effect similar to fluoxetine by reducing the level of despair presented by the reduction in duration of immobility compared to saline treated group. Nevertheless, fluoxetine showed to be more potent and efficacious than stigmasterol. Stigmasterol showed to be more 2.6 times potent in the forced swim test compared to the tail suspension test. This disparity observed may be due to the distinct neurobiological sensitivity of the two paradigms. While the tail suspension test is more sensitive to agents acting on noradrenergic and dopaminergic pathways, the forced swim test shows greater sensitivity to serotonergic modulation54,55. To confirm monoamine involvement in this observed antidepressant-like activity, pre-treatment with Reserpine, a vesicular monoamine transporter (VMAT) inhibitor marginally reversed the activity of stigmasterol. Depletion of norepinephrine stores by AMPT seem to have potentiated the antidepressant-like activity of stigmasterol while depletion of serotonin stores by pCPA significantly reversed the observed antidepressant-like activity of stigmasterol in the forced swim test. Serotoninergic role in stigmasterol’s antidepressant-like effects was further confirmed when ondansetron and pizotifen were used to selectively block 5HT3 and 5HT2 receptors respectively. Reversal of antidepressant-like activity was observed in ondansetron pretreated groups but not in pizotifen pretreated group suggesting more involvement of 5-HT receptors but Propranolol, a non-selective beta adrenoceptor antagonist, marginally reversed the observed antidepressant-like activity of stigmasterol. Similar observation was reported by Ghosh et al.16 using prazosin, a α1 -adrenoceptor antagonist, to assess the role of the adrenergic system in the antidepressant activity of stigmasterol. Multi-targets therapeutics are promising approaches for management of depressive disorders as it helps in overcoming significant limitations of monotherapies through modulation of multiple cellular pathways56. Stigmasterol, from our study, is presented as a promising multitarget compound for treatment of depression, targeting neuronal survival, neuroinflammation and serotonergic modulation. Method Network pharmacology Screening for stigmasterol-related targets and depression-associated targets We screened for all possible biological targets of stigmasterol using online the databases GeneCard (https://www.genecards.org/), SwissTarget (http://www.swisstargetprediction.ch/) and PharmMapper (https://www.lilab-ecust.cn/pharmmapper/) with all databases accessed on 24th April, 2025. The SMILES and SDF of stigmasterol were acquired from the PubChem database and submitted to SwissTarget and PharmMapper respectively for identification of potential targets. Depression-associated genes were obtained from the OMIM (http://www.omim.org), PharmGKB (https://www.pharmgkb.org), DisGeNET (http://www.disgenet.org/) and GeneCards (https://www.genecards.org/) databases using the term s ‘Major Depressive Disorder’ as search keyword (accessed on 19th April, 2025). The UniProt database (https://www.UniProt.org/UniProt/) was employed to unify gene abbreviations. The intersection targets between stigmasterol-related genes and depression-associated genes were computed and the resultant venn diagram constructed using the bioinformatics tool Venn 2.1(https://bioinfogp.cnb.csic.es/tools/venny/ accessed on 25th April, 2025). Protein-protein interaction network construction and core target screening Analysis of protein–protein interactions (PPIs) is a crucial tool for understanding the complex involvement of proteins in various biochemical cascades. This approach aids in obtaining a comprehensive understanding of cellular architecture, biological processes, and functional modalities12. Intersection targets for stigmasterol and depression identified via network pharmacology were uploaded into the STRING database (https://string-db.org accessed on 25th April, 2025) to obtain the PPI network. The species type was limited to “homo sapiens,” with the interaction confidence score threshold set to 0.4. The resulting PPI network was visualized and a network analysis was performed using Cytoscape 3.10.0 software. The topological properties of targets were analyzed using the CytoHubba tool (a plug-in of Cytoscape), in order to identify key target genes with high connectivity based on their degree of centrality (DC). Targets with higher degree indicate they might be the primary targets in the molecular mechanism. Function enrichment analysis We further examined the intersecting gene targets for Gene ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Gene Ontology (GO) analysis is an important method for annotating genes and determining biological properties such as cellular component (CC), molecular function (MF), and biological process (BP)57. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses explores the functions of various pathways of the intersecting genes that have been identified27. The gene ontology tool, Shiny GO (http://bioinformatics.sdstate.edu/go/ accessed on 12th September, 2025) was used for CC, MF, BP and KEGG pathway analysis of hub genes. Molecular docking Molecular docking was performed using Maestro V13.5 from the Schrödinger Suite 2023-1 to validate the interaction between stigmasterol and the selected protein targets (Table 3.1). Docking protocols described by Abebe et al.58 and Chennai et al.59 were employed for the molecular docking. Ligand preparation The 3D SDF file of the ligand, stigmasterol (CAS number: 83-48-7), was obtained from Pubchem (https://pubchem.ncbi.nlm.nih.gov/, accessed on 15th September, 2025). Additionally, as a point of reference, the structures of standard drugs or compounds with proven interactions with selected protein targets were obtained from PubChem. The structures were imported to Maestro and prepared with the Ligprep module in Maestro. Different ionization states and chirality were generated using Epik with salts removed at pH = 7.2±2.0. Additionally, OPLS4 force field was selected for energy minimisation. All ligands generated were then docked against generated receptor grids using the glide ligand docking module. Protein preparation The crystal structures of candidate proteins were obtained from RCSB Protein Data Bank (RCSB PDB, https://www.rcsb.org/). Candidate protein targets for major depressive disorder were selected based on results obtained from the protein-protein interaction (PPI) analyses and their role in enriched pathways as well as the processes in the GO and KEGG enrichment analyses. The protein preparation wizard was used for preparation of candidate proteins by removing water molecules beyond 5 Å from the het group, filling in missing side chains, adding hydrogen, and energy optimisation at OPLS4 force field. Receptor grid generation Receptor grids at the active site of protein targets were generated by selecting the co-crystallised ligand to perform specific site docking, with a 10.0 ˚A radius binding site. The van der Waals radii of the receptor atoms were set with a partial atomic charge scaling factor of 1.0 and a partial cut of 0.25 to soften the receptor’s nonpolar parts. Ligand docking Using the Glide module in Maestro V13.5 from the Schrödinger Suite 2023-1, ligand docking was performed. With flexible ligand sampling with extra precision (XP) selected, prepared ligands were docked against generated receptor grid at the binding site of selected target proteins. All other parameters were kept at default to report best pose with the highest docking scores. Docking scores in kcal/mol were used to analyze the binding affinity. All analyses and procedures were performed using the Schrodinger suite of programs. Prior to the docking of stigmasterol, the co-crystallized ligands were prepared and docked using the same protocol as described above to validate the docking protocol. Ensuring RMSD after superposition were below 2.0 A. Induced fit docking Based on the docking scores of docked ligands, the best pose with favorable interaction of stigmasterol, co-crystalized ligands and standard ligand were selected for induced fit docking study. The protocol descried by Mili et al.60 was used for this study. For the IFD study, the induced fit model in Maestro Schrödinger suit was utilized. Van der Waal scaling was set at 0.5 and maximum 20 poses for a single ligand was selected. Within 5 Å, refinement of all the residues of the side chain and ligand pose was done. Glide redock was also set at extra precision. IFD scores were then calculated for each pose. Prime MM-GBSA Calculations Prime MM-GBSA was utilized to accurately calculate the binding free energy (ΔG) of docked complexes obtained in the Glide redock extra precision in the IFD study. Protocol described by Adam et al.48 was followed for this study. The variable surface generalized born (VSGB 2.0) solvation model and OPLS4 force field was used to determine the binding energy. The binding affinity was calculated by finding the difference in energies of the protein–ligand’s complex and its individual components. Validation of docking protocol Prior to the docking of stigmasterol, the co-crystallized ligands were prepared and docked using the same protocol as described above to validate the docking protocol, ensuring RMSD after superposition were below 2.0 A, and to also predict the binding affinities of the co-crystallized ligands. In Vivo experimental validation Animals Male and female inbred Institute of Cancer Research (ICR) mice (20–30 g; 8–10 weeks old) purchased from the Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana, were used for all behavioural assays. They were housed in groups of 7 in mouse housing cages with wood shaving as bedding. All experimental mice were housed in controlled conditions of 25±2°C temperature and 60–80% humidity while light was alternated in 12 h light/dark cycle. Food was normal mouse pellet diet and tap water was given ad libitum. The National Institute of Health Guidelines for the Care and Use of Laboratory Animals was followed for all procedures and technique. Post all behavioural studies, mice were euthanized by cervical dislocation. Ethical clearance was obtained from the IRB of the Ghana Council for Scientific Research into Plant Medicine (CSIR) (RP001/CSIR-IACUC/2024). In addition, the study is reported in accordance to the ARRIVE guidelines. Antidepressant-like activity To confirm the antidepressant potential of stigmasterol, two acute mouse models of depression were employed. Mice were randomly assigned to groups (n=7), and received either stigmasterol (1, 3, 10, 30, 100 mg kg−1) i.p or fluoxetine (1, 3, 10, 30 mg kg−1) p.o or saline 10 ml kg−1. The mice were then subjected to the tail suspension test 30 minutes after i.p administration or 60 minutes after p.o administration. This was followed 30 minutes later by the forced swim test. The tail suspension test was done as described by Steru et al.61 with slight modifications. Mice were held by their tail (1 cm from the tip) on a horizontal bar raised 50 cm from the benchtop using an adhesive tape. Every mouse was individually recorded for 6 min for escape-oriented behaviour using a camera. Videos were later scored for the duration of immobility with JWatcher™. The forced swim test with slight modifications as described in Biney et al.62 was used. Each mouse was allowed to swim for 6 minutes in cylindrical tanks filled with water to a depth of 15 cm. The session was recorded and the duration of immobility during the last 4 minutes of the test quantified using JWatcher™. Evaluating possible mechanism(s) of antidepressant-like action of stigmasterol Influence of monoamines Results obtained from the network pharmacology and molecular docking implicated monoaminergic pathways as potential targets for stigmasterol’s biological effects. To experimentally validate the possible involvement of monoamines in the antidepressant-like effect of stigmasterol, storage and/or synthesis of monoamines was inhibited based on previous studies63,64. Mice were assigned to two groups; one group pre-treated with a single dose of reserpine (1 mg kg−1) and the other with 10 ml kg−1 distilled water. Mice in both groups subsequently received either the vehicle or equipotent doses of stigmasterol (30 mg kg−1), fluoxetine (30 mg kg−1) or imipramine (30 mg kg−1) 18 hours after reserpine pretreatment before repeating the forced swim test. Selective inhibition of 5-HT synthesis was achieved by pretreatment with p-chlorophenylalanine (pCPA), a tryptophan hydroxylase inhibitor. This paradigm was used to assess the role of 5-HT in the observed antidepressant-like effect of stigmasterol. Mice were assigned to two groups: one group receiving pCPA (100 mg kg−1 i.p.) pre-treatment, daily for 4 consecutive days and the other, 10 ml kg−1 normal saline for the same period. Twenty-four hours after the last pCPA pretreatment, the groups received distilled water or equipotent doses of stigmasterol (30 mg kg−1) i.p, fluoxetine (30 mg kg−1) or imipramine (30 mg kg−1) o.s. The forced swim test was repeated one hour after stigmasterol, fluoxetine or imipramine administration. Lastly, a single dose of the tyrosine hydroxylase inhibitor, α-methyl-p-tyrosine (AMPT) (100 mg kg−1 i. p.), was used to deplete catecholamine stores to assess the influence of catecholamines on the antidepressant-like activity of stigmasterol. Mice were grouped into pre-treated and untreated groups. The pretreated group received a single dose of AMPT while the untreated group received 10 ml kg−1 distilled water. Four hours later both groups received equipotent doses of either stigmasterol (30 mg kg−1) i.p, fluoxetine (30 mg kg−1) or imipramine (30 mg kg−1) p.o. Behavioral assessment was repeated using the FST one hour post drug treatment. Influence on specific monoamine receptors To examine the implication of 5-HT and norepinephrine receptors, mice were either pre-treated with ondansetron (3 mg kg−1) or pizotifen (10 mg kg−1) or propranolol (3 mg kg-1) p.o. or distilled water before administration of equipotent doses of stigmasterol (30 mg kg−1), or fluoxetine (30 mg kg−1) after which the forced swim test was repeated. Data analysis Behavioural data collected were analysed using GraphPad Prism 9.0 (GraphPad Software, San Diego, CA, USA). Data is organized as bar graphs with individual data points showing bars that represent mean ± standard error of mean. Data was analysed for normality and when normally distributed, bar graphs are further analysed by one-way analysis of variance (ANOVA) following which post hoc tests for multiple comparisons were conducted using the Tukey’s honest significant difference (HSD) test. In pre-treatment using pharmacological antagonism assays, results were analysed by 2-way ANOVA (mixed effects model) followed by Sidak multiple comparison test with antagonist pre-treatment and drug treatment as dependent variables. Functional enrichment analyses were computed with gene ontology tool, Shiny GO. Enriched terms were selected after a threshold of p≤0.05, following the false discovery rate (FDR) determined via the Benjamini–Hochberg method. In molecular docking experiments, all the analyses were performed using the Schrodinger suite of programs. Conclusion This study presents a novel perspective concerning the molecular mechanism of stigmasterol against depression. Further pharmacological experiments should be conducted to explore antidepressant-like activity in chronic models of depression including depression as a result of neuroinflammation as well as assaying of neurogenesis and neuronal survival.